Anacor Pharmaceutical

edit

Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases.

The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.

Milestones

edit

• Received $50M in Series E funding. (1/6/09)
  Posted 6/18/09 at 10:36pm
• Received $50M in Unattributed funding. (2/5/07)
  Posted 6/19/09 at 10:28am

Videos

Screenshots

edit

Above: Anacor Pharmaceutical Screenshot -- #1
Uploaded: 6/19/09

Sources

1. Anacor Raises $50 Million in Equity Financing (bio-medicine.org) [edit]
2. Anacor, anti-fungal therapy co., gets $50M from Schering-Plough (deals.venturebeat.com) [edit]